Self-Assembling Peptide Scaffolds for Faster Subunit Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing subunit vaccines are time-consuming, labor-intensive, and costly, requiring recombinant protein expression in hosts like bacteria, yeast, and mammalian cells.
Innovation Solution
Development of self-assembling monomer peptides that form dimers, trimers, or hexamers through solid phase peptide synthesis, which include T-cell epitopes and can be conjugated with haptens to induce a robust immune response, eliminating the need for traditional recombinant expression hosts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant protein expression in hosts (bacteria, yeast, mammalian cells) is used to produce subunit vaccines, then vaccine production can be achieved through established methods, but the process becomes time-consuming, labor-intensive, and costly
Solution Approach 1:
The patent extracts and utilizes only the essential immunogenic components (epitopes) from pathogen proteins, rather than producing entire recombinant proteins. This extraction approach eliminates the need for complex recombinant expression systems while retaining the core vaccine function, thereby reducing production time and complexity
Solution Approach 2:
The patent creates simplified copies of the essential immunogenic elements (peptide epitopes) through chemical synthesis rather than biological expression. These synthetic peptide copies replicate the key functional features needed for immune recognition without requiring the complex machinery of recombinant protein production, thus accelerating development and reducing costs
2Ease of manufacture
If recombinant protein expression in hosts is used to produce subunit vaccines, then vaccine components can be produced through biological systems, but the process becomes labor-intensive and costly
Solution Approach 1:
The patent replaces the biological/mechanical recombinant expression system with a chemical synthesis system. Solid-phase peptide synthesis and automated coupling reactions substitute for complex biological processes involving host cell culture, protein expression, and purification, thereby simplifying manufacturing and improving productivity
Solution Approach 2:
The patent changes the fundamental production parameter from biological expression (requiring living hosts, controlled environments, and complex media) to chemical synthesis (using standardized reagents and automated protocols). This parameter change transforms a labor-intensive biological process into a more efficient chemical manufacturing process
3Reliability
If traditional recombinant expression hosts are used for vaccine production, then protein subunits can be produced through established biological methods, but production costs increase
Solution Approach 1:
The patent employs inexpensive, easily synthesized peptide building blocks that can be rapidly produced through solid-phase synthesis. These short-lived, easily replaceable peptide components substitute for expensive recombinant protein production, significantly reducing manufacturing costs while maintaining reliable vaccine production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces production time and costs by synthesizing vaccine components efficiently, allowing for a robust immune response and targeted delivery of haptens and therapeutic agents in vivo.
Implementation Method 1
monomer peptides comprising two or more heptads that self-assemble into a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, nanomer, or decamer
Implementation Method 2
The Hexameric hapten carriers (HhC) further include one or more haptens conjugated to it
Data Source
AI summary
The present disclosure describes a peptide scaffold for producing vaccines. The peptide scaffold includes a peptide that self-assembles into a hapten carrier (hC) that includes amphipathic alpha-helices. The peptide includes heptad repeats following a specific pattern. The hC further includes hapten or an agent conjugated to it, and optionally the hC includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the hapten-hC or agent-hC conjugate.